Biotech | April 08, 2026
Stipple Bio raises $100M Series A to advance next-gen cancer therapies
The new capital is expected to fund the company through 2029
The new capital is expected to fund the company through 2029
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Safety was equally impressive. ENV-294 was well tolerated
Collaboration to study integration of AI-enabled VR solutions into medical and nursing curricula
Subscribe To Our Newsletter & Stay Updated
